Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor

The first and only non-covalent  BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition
In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least...

Related Keywords

United States ,Texas ,Prnewswire Eli Lilly ,Williamg Wierda ,Brian Koffman ,Joe Fletcher ,Eli Lilly ,Kyle Owens ,Jacob Van Naarden ,Instagram ,Linkedin ,Lilly United States ,Lymphoma Society ,Department Of Leukemia ,Laboratory Abnormalities ,University Of Texas Md Anderson Cancer Center ,Facebook ,Exchange Commission ,Drug Administration ,National Cancer Institute ,International Workshop On Chronic Lymphocytic Leukemia ,Important Safety Information ,Prescribing Information ,Chronic Lymphocytic Leukemia ,Chronic Lymphocytic ,Small Lymphocytic Lymphoma ,Primary Malignancies ,Fetal Toxicity ,Patients Who Received ,Special Populations ,Renal Impairment ,Patient Information ,Private Securities Litigation Reform Act ,United States Securities ,Treasure Island ,Statpearls Publishing ,Cancer Stat Facts ,Markets ,